Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Of la,25-dihydroxy vitamin

H9. Hedlund, T. E., Moffatt, K. A., and Miller, G. J., Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1 Evidence that the antiproliferative effects of la, 25-dihydroxy vitamin D3 are mediated through the genomic signalling pathway. Endocrinology 137, 1554-1561 (1996). [Pg.147]

In the context of the synthesis of a precursor of la,25-dihydroxy vitamin D3, Posner and Kinter treated allylic alcohol (115) with ethyl orthoacetate in a sealed tube. - The resultant 7,8-unsaturated ester... [Pg.839]

In the catalyzed inverse electron demand Diels-Alder reaction of dienophile 1 with diene 2, a d.r. of 98 2 is observed. The adduct 3 is converted into the key synthon of la,25-dihydroxy-vitamin D382. [Pg.637]

Within the total synthesis of new A-ring analogues of la,25-dihydroxy-vitamin D3, an acrylic ester derivative was transformed to an allylphosphine oxide via reduction, halogenation and P-functionalization (Scheme 14). ... [Pg.57]

Strathmann, R, Laha, T., and Hoofnagle, A. 2011. Qnantification of la,25 dihydroxy vitamin D by immunoextraction and hquid chromatography-tandem mass spectrometry. Clin. Chem. 57 1279-1285. [Pg.274]

Bravo, S., Paredes, R., Izaurieta, P., et al. 2006. The classic receptor for 1 alpha,25-dihydroxy vitamin D3 is required for non-genomic actions of la,25-dihydroxy vitamin d3 in osteosarcoma cells. J. Cell Biochem. 99 995-1000. [Pg.80]

Mourino, A., Torneiro, M., Vitale, C., Fernandez, S., Perez-Sestelo, J., Anne, S. and Gregorio, C. (1997) Effident and versatile synthesis of A-ring precursors of la,25-dihydroxy-vitamin Dj and analogues. Application to the synthesis of Lythgoe-Roche phosphine oxide. Tetrahedron Letters, 38, 4713-4716. [Pg.248]

An efficient synthetic route to (10Z)- and (10 )-19-lluoro-la,25-dihydroxy vitamin D3 has been developed (488). The key feature of this pathway is the introduction of a 19-fluoromethylene group to a (5 )-19-nor-10-oxo-vitamin D derivative. The 10-oxo compound 445 has been obtained via a 1,3-dipolar cycloaddition reaction of (5 )-la,25-dihydroxyvitamin D with in situ generated nitrile oxide, followed by ring cleavage of the formed isoxazoline moiety with molybdenum hexacarbonyl. Conversion of the keto group of (5 )-19-nor-10-oxo-vitamin D to the E and Z fluoromethylene group has been achieved via a two-step sequence, involving a reaction of lithiofluoromethyl phenyl sulfone, followed by the reductive de-sulfonylation of the u-lluoro-j3-hydroxysulfone. The dye-sensitized photoisomerization of the (5 )-19-fluorovitamin D affords the desired (5Z)-19-fluorovitamin D derivatives, (10Z)- and (10 )-19-fluoro-la,25-dihydroxy-vitamin D3. [Pg.98]

TF transcription factor, R receptor, Fur ferric uptake regulation protein, NF-kB nuclear factor-kB, AP-1 activator protein-1, Egr-1 early growth response-1, VDR la,25-dihydroxy-vitamin D3 receptor, RXR retinoid X receptor, PPARy peroxisome proliferator-activated receptor y NFAT nuclear factor of activated T-cells, HSF heat shock factor, p53 tumor suppressor p53, HIF-1 hypoxia inducible factor-1. ... [Pg.331]

There seems to be no metabolic control exerted on hepatic 25-hydroxylase and so all of the available cholecalciferol is converted. Hydroxylation in the kidney however is an important control point being regulated by PTH, and indirectly therefore by calcium and phosphate concentrations. Stimulation of la-hydroxylase by PTH is via a cyclic AMP (cAMP) -dependent mechanism and longer-term regulation of the activity of this enzyme is via induction mediated by other hormones such as oestrogens, cortisol and growth hormone. Typically, the plasma concentration of 1,25 dihydroxy vitamin D is in the range 20-60 ng/1, that is approximately 1000-times lower than that of its precursor. [Pg.300]

When 1,25 DHCC provision is adequate or when plasma calcium concentration is above approximately 2.20mmol/l, la hydroxylase activity is suppressed and 25-hydroxy vitamin D3 is converted by 24-hydroxylase into 24,25 dihydroxy vitamin D3 a metabolite whose true role is uncertain but one which seems to have little if any physiological activity. Renal 24-hydroxylase does have a role to play in the deactivation of 1,25 dihydroxy vitamin D the major metabolite of the vitamin being 1,24,25 trihydroxy vitamin D. [Pg.300]

Kleuser, B., Cuvillier, O., and Spiegel, S., 1998, la,25-dihydroxy vitamin D3 inhibits programmed cell death in HL-60 cells by activation of sphingosine kinase. Cancer Res. [Pg.281]

The active forms of the D vitamins are la,25-dihydroxy-vitamin Dj and 25-hydroxy-vitamin Dj. They are formed by enzymatic hydroxylation in the liver microsomes and then in the kidney mitochondria by a ferredoxin flavoprotein and cytochrome P-450. The 1,25-dihydroxy vitamin is then transported to the bone, intestine, and other target organs (kidneys, parathyroid gland). Consequently, it can be considered a hormone since it is produced in one organ but used elsewhere. It mobilizes calcium and phosphate and also influences the absorption of these ions in the intestine, thus promoting bone mineralization. The hormone is also active in relieving hypoparathyroidism and postmenopausal osteoporosis, which, for example, results in the brittle bones of elderly women. [Pg.510]

Schroder and co-workers (Schroder etal., 1999,2000) studied PolyP metabolism in bone tissues and osteblast cultures. They revealed that PolyP metabolism in human osteoblasts was modulated by stimulators of osteoblast proliferation and differentiation (Leyhausen et al., 1998). A combined treatment of the cells with dexamethasone, ft-glycerophosphate, epidermal growth factor (EGF), and ascorbic acid resulted in a dramatic decrease in PolyP content. This decrease is caused mainly by a decrease in the amount of soluble long-chain PolyPs. The amount of this PolyP fraction, but not the amount of insoluble long-chain PolyPs, further decreases after additional treatment of the cells with la, 25-dihydroxy vitamin D3. The decrease in PolyP content during treatment with dexamethasone, ft-glycerophosphate, EGF and ascorbic acid is accompanied by a decrease in exopolyphosphatase activity. However, additional treatment with la, 25-dihydroxyvitamin D3 results in a significant increase of the enzyme activity. Therefore, it is reasonable to assume that PolyP... [Pg.180]

Recent findings show that vitamin D3 must be hydroxylated at C-25 by the liver and then at C-la by the kidney to 1 a,25-dihydroxy-vitamin D3 before it can induce calcium transport. It is therefore not surprising to find several reports on the synthesis of both the la,25-dihydroxy-vitamin and la,25-hydroxycholesterol. [Pg.316]

CH(Me)(CH2)2CH=CMe2 and CH(Me)(CH2)3C(Me)=CH2. The 25-hydroxy-group was restored at the end of the synthesis. Successive acetylation, bromination, dehydrobromination, saponification, and irradiation when applied to la,25-dihydroxycholesterol convert it either into la,25-dihydroxy-previtamin D3128 or into a la,25-dihydroxy-vitamin D3,129 depending on reaction conditions. [Pg.316]

Cycloaddition of 4-phenyl-3//-l,2,4-triazole-3,5(4//)-dione to provitamin D3 affords exclusively the product formed by addition to the least hindered a-face of the more reactive diene, the structure was determined by X-ray8. The diastereoselectivity appears to be determined by the steric effect of the rran.v-hydrindane system, although the mechanism has not been elucidated. The cycloaddition of 4-phenyl-3//-l,2,4-triazole-3,5(4//)-dione was exploited to temporarily protect the diene group in the syntheses of la-hydroxy vitamin D3 7 a(X = H)8,9 and la,25-dihydroxy vitamin D3 7b (X = OH, starting from 25-hydroxy provitamin D3)10. Complete stereocontrol was observed in the cycloreversion step. For related cycloadditions to vitamin D3 see Section 7.2,10.3.4. [Pg.995]

Basic research on the synthesis of analogs of the biologically active form of vitamin D3, la,25-dihydroxy vitamin D3 (la,25(OH)2D3) has led to the development of an important new field in medicinal chemistry [84]. We have also reported symmetry assisted enantiospecific synthesis of the A-ring of the vitamin D hybrid analogs, 19-nor-22-oxa-la,25(OH)2D3 (Sch. 29) [85], It should be noted here that extremely high 1,3-frans selectivity was achieved by combining the (f )-BINOL-Ti catalyst and the (i )-ene substrate without geminal disubstitution. [Pg.816]

The cyclohexyl fragment of FK-506 (Scheme 6.62) [85] and la,25-dihydroxy-Vitamin D3 Ring A synthon (Scheme 6.63) [87] were readily accessible by trans- and cis-selective cychzation, respectively. [Pg.233]

The vitamin D receptor (VDR/NR1I1) is a member of the superfamily of steroid hormone receptors. It regulates calcium homeostasis, cell proliferation, and differentiation, and exerts immunomodulatory and antimicrobial functions [119]. VDR binds to and mediates the calcemic effects of calcitriol (la,25-dihydroxy vitamin D3) after forming an heterodimer with RXR. la,25-dihydroxyvitamin D3 negatively regulates its own synthesis by repressing the 25-hydroxyvitamin D3 la-hydroxylase (CYP27B1) in a cell-type selective event that involves different combinations of multiple VDR response elements [120, 121]. [Pg.285]


See other pages where Of la,25-dihydroxy vitamin is mentioned: [Pg.167]    [Pg.480]    [Pg.1449]    [Pg.1449]    [Pg.79]    [Pg.118]    [Pg.167]    [Pg.480]    [Pg.1449]    [Pg.1449]    [Pg.79]    [Pg.118]    [Pg.348]    [Pg.480]    [Pg.483]    [Pg.92]    [Pg.794]    [Pg.794]    [Pg.263]    [Pg.522]    [Pg.528]    [Pg.535]    [Pg.984]    [Pg.516]    [Pg.483]    [Pg.454]    [Pg.496]   
See also in sourсe #XX -- [ Pg.3 , Pg.11 , Pg.384 , Pg.385 ]




SEARCH



Dihydroxy vitamin

© 2024 chempedia.info